{"hands_on_practices": [{"introduction": "Understanding the quantitative consequences of a genetic mutation is a cornerstone of modern immunology. This exercise explores how a partial loss-of-function in the kinase IRAK4, a known cause of primary immunodeficiency, impacts a downstream cellular response. By applying the principles of Michaelis-Menten enzyme kinetics and the Hill equation for signal amplification, you will model how the innate immune signaling pathway translates a reduction in catalytic activity into a final cytokine output, providing insight into the concept of ultrasensitivity [@problem_id:2871874].", "problem": "A loss-of-function variant of Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) is a well-characterized cause of primary immunodeficiency that impairs Toll-like Receptor (TLR) and Interleukin-1 receptor signaling to Nuclear Factor kappa-light-chain enhancer of activated B cells (NF-κB), reducing Interleukin-6 (IL-6) production. Consider a simplified receptor-proximal step in which IRAK4 phosphorylates a single proximal substrate in the myddosome (for example, IRAK1) under the quasi-steady-state regime of enzyme catalysis. The catalytic flux $v$ from this step is transmitted downstream to IL-6 transcription through an ultrasensitive signaling amplifier that can be modeled as a Hill-type input-output function of the upstream flux.\n\nAssume the following biologically plausible and self-consistent conditions:\n- The enzyme-catalyzed reaction follows the quasi-steady-state approximation for a one-substrate mechanism $E + S \\rightleftharpoons ES \\rightarrow E + P$ with total enzyme concentration $[E]_{T}$ and turnover number $k_{\\mathrm{cat}}$, yielding a catalytic flux $v$ that depends on the Michaelis constant $K_{M}$ and substrate concentration $[S]$.\n- Wild-type parameters: $k_{\\mathrm{cat}}^{\\mathrm{WT}} = 5\\,\\mathrm{s}^{-1}$, $[E]_{T} = 50\\,\\mathrm{nM}$, $K_{M} = 0.5\\,\\mu\\mathrm{M}$, and $[S] = 1.0\\,\\mu\\mathrm{M}$.\n- The IRAK4 variant reduces catalytic activity to $10\\%$ of wild-type, that is $k_{\\mathrm{cat}}^{\\mathrm{mut}} = 0.10 \\times k_{\\mathrm{cat}}^{\\mathrm{WT}}$, without changing $[E]_{T}$, $K_{M}$, or $[S]$.\n- The downstream amplifier mapping upstream flux $v$ to normalized IL-6 output $O$ (a dimensionless fraction of maximal attainable IL-6 transcriptional output) is given by a Hill function with coefficient $n=2$ and half-maximal flux $J = 50\\,\\mathrm{nM}\\,\\mathrm{s}^{-1}$.\n\nUsing only these assumptions and the general framework above, compute the fractional IL-6 output of the mutant relative to wild-type,\n$$\nR \\equiv \\frac{O_{\\mathrm{mut}}}{O_{\\mathrm{WT}}}.\n$$\nGive your final answer as a single exact number (do not round; no units).", "solution": "The problem statement has been subjected to rigorous validation and is deemed scientifically grounded, well-posed, and objective. It provides a self-consistent and formalizable model of a biological signaling pathway, using standard principles of enzyme kinetics and systems biology. All necessary parameters are provided, and their values are biologically plausible. We may therefore proceed with the solution.\n\nThe problem requires us to compute the ratio of the mutant IL-6 output to the wild-type IL-6 output, $R \\equiv \\frac{O_{\\mathrm{mut}}}{O_{\\mathrm{WT}}}$. The solution involves a two-step calculation: first, determining the catalytic flux $v$ for both wild-type and mutant enzymes using the Michaelis-Menten equation, and second, using these fluxes as inputs to the Hill function to determine the respective outputs $O$.\n\nThe catalytic flux $v$ is described by the Michaelis-Menten equation for a single-substrate reaction under the quasi-steady-state approximation:\n$$\nv = \\frac{k_{\\mathrm{cat}} [E]_{T} [S]}{K_{M} + [S]}\n$$\nwhere $k_{\\mathrm{cat}}$ is the turnover number, $[E]_{T}$ is the total enzyme concentration, $[S]$ is the substrate concentration, and $K_{M}$ is the Michaelis constant.\n\nThe normalized output $O$ is given by the Hill function:\n$$\nO = \\frac{v^n}{J^n + v^n}\n$$\nwhere $n$ is the Hill coefficient and $J$ is the half-maximal flux.\n\nFirst, we must ensure all parameters are in a consistent set of units. We will convert all concentrations to nanomolar ($nM$) and rates to $\\mathrm{nM}\\,\\mathrm{s}^{-1}$.\nThe given parameters are:\n- Wild-type turnover number: $k_{\\mathrm{cat}}^{\\mathrm{WT}} = 5\\,\\mathrm{s}^{-1}$\n- Total enzyme concentration: $[E]_{T} = 50\\,\\mathrm{nM}$\n- Michaelis constant: $K_{M} = 0.5\\,\\mu\\mathrm{M} = 500\\,\\mathrm{nM}$\n- Substrate concentration: $[S] = 1.0\\,\\mu\\mathrm{M} = 1000\\,\\mathrm{nM}$\n- Hill coefficient: $n = 2$\n- Half-maximal flux: $J = 50\\,\\mathrm{nM}\\,\\mathrm{s}^{-1}$\n\nNow, we calculate the catalytic flux for the wild-type (WT) case, denoted as $v_{\\mathrm{WT}}$:\n$$\nv_{\\mathrm{WT}} = \\frac{k_{\\mathrm{cat}}^{\\mathrm{WT}} [E]_{T} [S]}{K_{M} + [S]} = \\frac{(5\\,\\mathrm{s}^{-1}) (50\\,\\mathrm{nM}) (1000\\,\\mathrm{nM})}{500\\,\\mathrm{nM} + 1000\\,\\mathrm{nM}}\n$$\n$$\nv_{\\mathrm{WT}} = \\frac{250000}{1500} \\,\\mathrm{nM}\\,\\mathrm{s}^{-1} = \\frac{2500}{15} \\,\\mathrm{nM}\\,\\mathrm{s}^{-1} = \\frac{500}{3} \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}\n$$\n\nFor the mutant (mut) case, the catalytic activity is reduced to $10\\%$ of wild-type. Let $\\alpha = 0.10$.\nThe mutant turnover number is $k_{\\mathrm{cat}}^{\\mathrm{mut}} = \\alpha \\times k_{\\mathrm{cat}}^{\\mathrm{WT}} = 0.10 \\times 5\\,\\mathrm{s}^{-1} = 0.5\\,\\mathrm{s}^{-1}$.\nSince $[E]_{T}$, $K_{M}$, and $[S]$ are unchanged, the mutant flux $v_{\\mathrm{mut}}$ is directly proportional to the wild-type flux:\n$$\nv_{\\mathrm{mut}} = \\frac{k_{\\mathrm{cat}}^{\\mathrm{mut}} [E]_{T} [S]}{K_{M} + [S]} = \\frac{(\\alpha \\cdot k_{\\mathrm{cat}}^{\\mathrm{WT}}) [E]_{T} [S]}{K_{M} + [S]} = \\alpha \\cdot v_{\\mathrm{WT}}\n$$\n$$\nv_{\\mathrm{mut}} = 0.10 \\times \\frac{500}{3} \\,\\mathrm{nM}\\,\\mathrm{s}^{-1} = \\frac{50}{3} \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}\n$$\n\nNext, we calculate the respective outputs $O_{\\mathrm{WT}}$ and $O_{\\mathrm{mut}}$ using the Hill function. It is convenient to first compute the dimensionless ratios of the fluxes to the half-maximal flux $J$.\nFor the wild-type case:\n$$\n\\frac{v_{\\mathrm{WT}}}{J} = \\frac{500/3 \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}}{50 \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}} = \\frac{10}{3}\n$$\nThe wild-type output is:\n$$\nO_{\\mathrm{WT}} = \\frac{(v_{\\mathrm{WT}}/J)^n}{1 + (v_{\\mathrm{WT}}/J)^n} = \\frac{(10/3)^2}{1 + (10/3)^2} = \\frac{100/9}{1 + 100/9} = \\frac{100/9}{109/9} = \\frac{100}{109}\n$$\nFor the mutant case:\n$$\n\\frac{v_{\\mathrm{mut}}}{J} = \\frac{50/3 \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}}{50 \\,\\mathrm{nM}\\,\\mathrm{s}^{-1}} = \\frac{1}{3}\n$$\nThe mutant output is:\n$$\nO_{\\mathrm{mut}} = \\frac{(v_{\\mathrm{mut}}/J)^n}{1 + (v_{\\mathrm{mut}}/J)^n} = \\frac{(1/3)^2}{1 + (1/3)^2} = \\frac{1/9}{1 + 1/9} = \\frac{1/9}{10/9} = \\frac{1}{10}\n$$\n\nFinally, we compute the required ratio $R$:\n$$\nR = \\frac{O_{\\mathrm{mut}}}{O_{\\mathrm{WT}}} = \\frac{1/10}{100/109} = \\frac{1}{10} \\times \\frac{109}{100} = \\frac{109}{1000}\n$$\nThis result demonstrates the severe impact of a reduction in enzyme activity when coupled with an ultrasensitive downstream amplifier. A $90\\%$ reduction in catalytic rate leads to a reduction in final output to approximately $10.9\\%$ of the wild-type level under these specific substrate conditions.", "answer": "$$\n\\boxed{\\frac{109}{1000}}\n$$", "id": "2871874"}, {"introduction": "The development of a diverse and functional T-cell repertoire is governed by stochastic encounters within the thymus. This practice challenges you to model how a defect in antigen presentation, mimicking Bare Lymphocyte Syndrome, quantitatively impacts T-cell positive selection. Using a probabilistic framework based on the Poisson distribution, you will connect the molecular density of peptide-HLA complexes to the probability of successful thymocyte development, illustrating how cellular population dynamics can be sensitive to the abundance of key molecules [@problem_id:2871918].", "problem": "A hypomorphic mutation in the class II transactivator (CIITA) reduces Human Leukocyte Antigen class II (HLA-II) expression on cortical thymic epithelial cells (cTECs) to a fraction of its wild-type level, impairing positive selection of cluster of differentiation 4 (CD4) T cells and causing a clinical picture akin to Bare Lymphocyte Syndrome type II. Consider a single antigen-specific clone of CD4-lineage thymocytes whose positive selection requires at least one productive T-cell receptor (TCR) encounter with peptide–HLA-II on cTECs during a fixed dwell time window. Assume the following foundational model grounded in receptor–ligand encounter statistics and thymic selection principles:\n\n- Productive TCR–peptide–HLA-II encounters occur as a Poisson process with mean $\\mu=\\alpha D T$ over the dwell time $T$, where $\\alpha$ is a constant linking HLA-II surface density to encounter rate, and $D$ is the HLA-II density normalized to the wild-type (WT) level (so WT has $D=1$).\n- The probability of successful positive selection for this clone, denoted $P_{\\text{sel}}(D)$, equals the probability of at least one productive encounter during $T$.\n- Negative selection is negligible for this clone under the stated conditions, so the expected output of antigen-specific CD4 T cells is proportional to $P_{\\text{sel}}(D)$.\n\nIn a WT thymus with $D=1$, the empirically observed fraction of this clone that successfully passes positive selection is $0.5$. In the mutant thymus, HLA-II expression on cTECs is reduced to $D=0.1$.\n\nUsing the model above and keeping $\\alpha T$ fixed across conditions, compute the expected fold-change $F$ in antigen-specific CD4 T-cell output in the mutant relative to WT, defined as\n$$\nF \\equiv \\frac{P_{\\text{sel}}(D=0.1)}{P_{\\text{sel}}(D=1)}.\n$$\nProvide your answer as a dimensionless decimal factor and round to four significant figures.", "solution": "We model productive T-cell receptor (TCR) encounters as a Poisson process. Let $N$ be the number of productive encounters in dwell time $T$. By assumption, $N \\sim \\text{Poisson}(\\mu)$ with mean\n$$\n\\mu=\\alpha D T,\n$$\nwhere $D$ is the normalized Human Leukocyte Antigen class II (HLA-II) density and $\\alpha$ is a proportionality constant linking ligand density to encounter rate.\n\nThe probability of at least one productive encounter is a standard result for a Poisson process:\n$$\nP(N\\ge 1)=1-\\Pr(N=0)=1-\\exp(-\\mu)=1-\\exp(-\\alpha D T).\n$$\nBy the problem’s assumptions, the positive selection probability for the clone is\n$$\nP_{\\text{sel}}(D)=1-\\exp(-\\alpha D T).\n$$\nIn wild-type (WT) with $D=1$, we are given $P_{\\text{sel}}(1)=0.5$. Therefore,\n$$\n0.5=1-\\exp(-\\alpha \\cdot 1 \\cdot T)\\quad\\Longrightarrow\\quad \\exp(-\\alpha T)=0.5\\quad\\Longrightarrow\\quad \\alpha T=\\ln 2.\n$$\nIn the hypomorphic mutant, $D=0.1$, so\n$$\nP_{\\text{sel}}(0.1)=1-\\exp\\!\\big(-\\alpha\\cdot 0.1 \\cdot T\\big)=1-\\exp\\!\\big(-0.1\\,\\alpha T\\big)=1-\\exp\\!\\big(-0.1\\,\\ln 2\\big)=1-2^{-0.1}.\n$$\nThe requested fold-change $F$ is\n$$\nF=\\frac{P_{\\text{sel}}(0.1)}{P_{\\text{sel}}(1)}=\\frac{1-2^{-0.1}}{0.5}=2\\big(1-2^{-0.1}\\big).\n$$\nTo evaluate numerically, note that\n$$\n2^{-0.1}=\\exp\\!\\big(-0.1\\,\\ln 2\\big)\\approx \\exp(-0.069314718)\\approx 0.9330329915.\n$$\nThus,\n$$\n1-2^{-0.1}\\approx 1-0.9330329915=0.0669670085,\n$$\nand\n$$\nF\\approx 2\\times 0.0669670085=0.133934017.\n$$\nRounded to four significant figures,\n$$\nF\\approx 0.1339.\n$$\nThis means the antigen-specific CD4 T-cell output in the mutant is reduced to approximately $0.1339$ of the wild-type output under the specified model and assumptions.", "answer": "$$\\boxed{0.1339}$$", "id": "2871918"}, {"introduction": "A key skill for an immunologist is the ability to diagnose molecular defects from experimental data. This problem places you in the role of a clinical investigator analyzing a defect in store-operated calcium entry (SOCE), a frequent cause of immunodeficiency. By interpreting the results of a calcium flux assay that uses specific pharmacological probes like thapsigargin and ionomycin, you will practice the logical deduction required to pinpoint the faulty component within a complex signaling cascade, a critical exercise in translational immunology [@problem_id:2871873].", "problem": "A T lymphocyte sample from a child with recurrent infections is analyzed for cytosolic calcium concentration, $[\\mathrm{Ca}^{2+}]_i$, using a ratiometric dye whose normalized fluorescence ratio is denoted $R(t)$. Two standard perturbations are applied to localize a molecular lesion in store-operated calcium entry (SOCE): thapsigargin and ionomycin. The following protocols and outcomes are obtained.\n\n- Protocol $1$ (SOCE assay bypassing receptor signaling): Cells are perfused with nominally $\\;0\\;$ mM extracellular $\\mathrm{Ca}^{2+}$ buffer from $t=0$ s. At $t=60$ s, thapsigargin at $1\\;\\mu\\mathrm{M}$ is added. At $t=300$ s, the perfusate is switched to $\\;2\\;$ mM extracellular $\\mathrm{Ca}^{2+}$. Observation: thapsigargin in $\\;0\\;$ mM extracellular $\\mathrm{Ca}^{2+}$ produces a small transient increase in $R(t)$ with peak $\\Delta R \\approx 0.20$ by $t\\approx 120$ s, followed by a return toward baseline; after reintroduction of $\\;2\\;$ mM extracellular $\\mathrm{Ca}^{2+}$ at $t=300$ s, there is no appreciable sustained increase in $R(t)$ (additional $\\Delta R < 0.05$ over the subsequent $200$ s). In healthy control cells run in parallel, the same protocol yields a large, sustained increase upon $\\mathrm{Ca}^{2+}$ readdition with $\\Delta R \\approx 0.80$.\n\n- Protocol $2$ (ionophore assay bypassing channels and sensors): In continuous $\\;2\\;$ mM extracellular $\\mathrm{Ca}^{2+}$, ionomycin at $1\\;\\mu\\mathrm{M}$ is added at $t=60$ s. Observation: a rapid large increase in $R(t)$ with $\\Delta R \\approx 0.90$ occurs within $30$ s and then plateaus.\n\nAssume that antigen receptor stimulation (for example, T cell receptor, TCR) fails to elicit a $\\mathrm{Ca}^{2+}$ rise in these patient cells, consistent with their clinical immunodeficiency. Using only the distinct molecular requirements of thapsigargin-evoked SOCE versus ionomycin-evoked $\\mathrm{Ca}^{2+}$ entry, and the canonical sequence of events in receptor-proximal calcium signaling (phospholipase C gamma generates inositol 1,4,5-trisphosphate, endoplasmic reticulum store depletion is sensed by stromal interaction molecule $1$, which gates the ORAI$1$ pore of the calcium release-activated calcium channel), which of the following molecular defects are most consistent with the observed patterns? Select all that apply.\n\nA. Loss-of-function in stromal interaction molecule $1$ (STIM$1$)\n\nB. Loss-of-function in ORAI$1$ (the calcium release-activated calcium channel pore subunit)\n\nC. Loss-of-function in phospholipase C gamma (PLC$\\gamma$)\n\nD. Gain-of-function in stromal interaction molecule $1$ (STIM$1$) leading to constitutive clustering and channel activation", "solution": "The problem statement must first be validated for scientific and logical integrity.\n\nStep 1: Extract Givens\n- Sample: T lymphocytes from a child with recurrent infections.\n- Measurement: Cytosolic calcium concentration, $[\\mathrm{Ca}^{2+}]_i$, via normalized fluorescence ratio $R(t)$.\n- Protocol $1$ (SOCE Assay):\n  - Time $t=0$ s: Perfusion with $0$ mM extracellular $[\\mathrm{Ca}^{2+}]$.\n  - Time $t=60$ s: Addition of $1\\;\\mu\\mathrm{M}$ thapsigargin.\n  - Time $t=300$ s: Perfusate switched to $2$ mM extracellular $[\\mathrm{Ca}^{2+}]$.\n- Protocol $1$ Observations (Patient):\n  - After thapsigargin in $0$ mM $[\\mathrm{Ca}^{2+}]_{ext}$: Small transient increase, $\\Delta R \\approx 0.20$.\n  - After reintroduction of $2$ mM $[\\mathrm{Ca}^{2+}]_{ext}$: No significant sustained increase, $\\Delta R < 0.05$.\n- Protocol $1$ Observations (Control):\n  - After reintroduction of $2$ mM $[\\mathrm{Ca}^{2+}]_{ext}$: Large, sustained increase, $\\Delta R \\approx 0.80$.\n- Protocol $2$ (Ionophore Assay):\n  - Conditions: Continuous $2$ mM extracellular $[\\mathrm{Ca}^{2+}]$.\n  - Time $t=60$ s: Addition of $1\\;\\mu\\mathrm{M}$ ionomycin.\n- Protocol $2$ Observations (Patient):\n  - After ionomycin: Rapid, large increase, $\\Delta R \\approx 0.90$.\n- Additional Information:\n  - Antigen receptor stimulation (TCR) fails to elicit a $[\\mathrm{Ca}^{2+}]$ rise in patient cells.\n  - Canonical signaling pathway: Phospholipase C gamma (PLC$\\gamma$) $\\rightarrow$ Inositol 1,4,5-trisphosphate (IP$_3$) $\\rightarrow$ Endoplasmic Reticulum (ER) store depletion $\\rightarrow$ Stromal interaction molecule $1$ (STIM$1$) sensing $\\rightarrow$ Gating of ORAI$1$ pore of the calcium release-activated calcium (CRAC) channel.\n\nStep 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem describes a standard cell biology experiment for investigating store-operated calcium entry (SOCE), a fundamental process in lymphocyte activation. The reagents (thapsigargin, ionomycin), concentrations ($1\\;\\mu\\mathrm{M}$, $0$ mM, $2$ mM), time scales, and molecular components (PLC$\\gamma$, STIM$1$, ORAI$1$) are all standard and factually correct in the context of immunology and cell signaling. The described condition, a primary immunodeficiency caused by defective SOCE, is a known clinical entity. The problem is based on established scientific principles.\n- **Well-Posed**: The experimental data from two distinct protocols provide complementary information that allows for logical deduction of the defective component in the signaling pathway. The question is precise and asks for the molecular defect(s) most consistent with the given data. A logical and unique set of answers can be derived.\n- **Objective**: The problem is stated using objective, quantitative observations (changes in fluorescence ratio $\\Delta R$) and precise experimental protocols. It is free of subjectivity or ambiguity.\n\nStep 3: Verdict and Action\nThe problem statement is scientifically sound, well-posed, and objective. It contains no discernible flaws. Therefore, a full analysis is warranted.\n\n### Analysis of the System\n\nThe problem requires a systematic diagnosis of a defect in the T-cell calcium signaling pathway. The canonical sequence of events for SOCE is:\n$1$. A stimulus (e.g., TCR engagement) activates PLC$\\gamma$.\n$2$. PLC$\\gamma$ generates IP$_3$.\n$3$. IP$_3$ binds to IP$_3$ receptors on the ER, causing release of stored $[\\mathrm{Ca}^{2+}]$ into the cytosol. This is the initial transient phase.\n$4$. The resulting depletion of $[\\mathrm{Ca}^{2+}]_{ER}$ is sensed by the ER-resident protein STIM$1$.\n$5$. Upon sensing depletion, STIM$1$ oligomerizes, translocates to ER-plasma membrane junctions, and physically interacts with the ORAI$1$ channel.\n$6$. This interaction gates the ORAI$1$ channel, opening a pore for a large, sustained influx of extracellular $[\\mathrm{Ca}^{2+}]$ into the cytosol. This is the SOCE phase.\n\nThe pharmacological tools used dissect this pathway:\n- **Thapsigargin**: An inhibitor of the SERCA pump, which actively transports $[\\mathrm{Ca}^{2+}]$ from the cytosol into the ER. Its inhibition leads to a passive leak of $[\\mathrm{Ca}^{2+}]_{ER}$ into the cytosol, thus depleting ER stores and activating SOCE downstream of PLC$\\gamma$/IP$_3$ generation.\n- **Ionomycin**: A calcium ionophore that creates artificial pores in membranes, allowing $[\\mathrm{Ca}^{2+}]$ to flow down its large electrochemical gradient from the extracellular space into the cytosol. It bypasses the entire physiological machinery of receptors, sensors, and channels (PLC$\\gamma$, STIM$1$, ORAI$1$).\n\n### Evaluation of Experimental Data\n\n**Protocol $2$ (Ionomycin Assay):**\nThe addition of ionomycin in the presence of $2$ mM extracellular $[\\mathrm{Ca}^{2+}]$ results in a rapid and large increase in cytosolic $[\\mathrm{Ca}^{2+}]$ ($\\Delta R \\approx 0.90$). This result demonstrates several key points:\n- A large electrochemical gradient for $[\\mathrm{Ca}^{2+}]$ exists across the plasma membrane.\n- The fluorescent dye is functional and capable of reporting large changes in $[\\mathrm{Ca}^{2+}]_i$.\n- The cell's basic capacity to contain a high concentration of cytosolic calcium is intact.\nThis experiment effectively serves as a positive control, indicating that the defect is not a global inability to manage calcium, but rather a specific failure in the physiological entry mechanism. The defect must be upstream of the calcium influx itself, within the protein machinery that mediates it.\n\n**Protocol $1$ (SOCE Assay):**\n- **Phase $1$ (Thapsigargin in $0$ mM $[\\mathrm{Ca}^{2+}]_{ext}$):** The addition of thapsigargin causes a small, transient increase in $[\\mathrm{Ca}^{2+}]_i$ ($\\Delta R \\approx 0.20$). This is the expected result of $[\\mathrm{Ca}^{2+}]$ leaking from the finite ER stores after SERCA pump inhibition. This confirms that:\n  - Thapsigargin is active.\n  - The ER contains a baseline level of stored, releasable calcium.\n  - The pathway up to and including ER store depletion is functional.\n- **Phase $2$ (Re-addition of $2$ mM $[\\mathrm{Ca}^{2+}]_{ext}$):** In the patient's cells, there is no significant sustained increase in $[\\mathrm{Ca}^{2+}]_i$ ($\\Delta R < 0.05$). In contrast, healthy control cells exhibit a large, sustained increase ($\\Delta R \\approx 0.80$). This is the critical observation. Following ER store depletion by thapsigargin, the SOCE machinery (STIM$1$ and ORAI$1$) should be fully engaged. The failure to elicit calcium influx upon providing extracellular calcium indicates a severe defect in the core SOCE mechanism itself, i.e., in the steps that link ER store depletion to plasma membrane influx. The defect must lie in either the sensor (STIM$1$) or the channel (ORAI$1$).\n\n### Option-by-Option Analysis\n\n**A. Loss-of-function in stromal interaction molecule $1$ (STIM$1$)**\nA loss-of-function (LOF) mutation in STIM$1$ would render the protein unable to sense $[\\mathrm{Ca}^{2+}]_{ER}$ depletion, or unable to oligomerize and activate ORAI$1$. In Protocol $1$, thapsigargin would still deplete ER stores, but the \"empty\" signal would not be transduced to the ORAI$1$ channel. Consequently, upon re-addition of extracellular $[\\mathrm{Ca}^{2+}]$, there would be no SOCE, which is precisely what is observed ($\\Delta R < 0.05$). The response to ionomycin (Protocol $2$) would be normal, as ionomycin bypasses STIM$1$. This hypothesis is fully consistent with all provided data.\nVerdict: **Correct**.\n\n**B. Loss-of-function in ORAI$1$ (the calcium release-activated calcium channel pore subunit)**\nA LOF mutation in ORAI$1$ would result in a non-functional or non-conducting CRAC channel. In Protocol $1$, thapsigargin would deplete stores, and STIM$1$ would correctly sense this and attempt to gate ORAI$1$. However, because the ORAI$1$ pore is defective, no calcium influx would occur upon re-addition of extracellular $[\\mathrm{Ca}^{2+}]$. This outcome matches the observed failure of SOCE ($\\Delta R < 0.05$). The ionomycin response would be normal, as it provides an alternative pathway for calcium entry. This hypothesis is also fully consistent with all provided data.\nVerdict: **Correct**.\n\n**C. Loss-of-function in phospholipase C gamma (PLC$\\gamma$)**\nA LOF mutation in PLC$\\gamma$ would disrupt signaling immediately downstream of the TCR, preventing IP$_3$ generation and subsequent store release. This would explain the failure of TCR stimulation to elicit a $[\\mathrm{Ca}^{2+}]$ rise. However, the key experiment, Protocol $1$, uses thapsigargin to bypass the TCR-PLC$\\gamma$-IP$_3$ axis and directly deplete ER stores. A cell with a PLC$\\gamma$ defect should have perfectly normal STIM$1$ and ORAI$1$ function. Therefore, it should exhibit a normal response to thapsigargin, showing robust SOCE upon re-addition of extracellular $[\\mathrm{Ca}^{2+}]$, just like the healthy control. The patient's cells fail this test. Thus, a defect in PLC$\\gamma$ cannot account for the results of the thapsigargin experiment.\nVerdict: **Incorrect**.\n\n**D. Gain-of-function in stromal interaction molecule $1$ (STIM$1$) leading to constitutive clustering and channel activation**\nA gain-of-function (GOF) mutation in STIM$1$ would cause the protein to be constitutively active, leading to persistently open ORAI$1$ channels, independent of the ER store content. This would result in elevated resting cytosolic $[\\mathrm{Ca}^{2+}]$ and potential cytotoxicity. The observed experimental phenotype is a *failure to activate* calcium influx, not a constitutive influx. If SOCE were constitutively active, the baseline calcium would be high, and the thapsigargin protocol would not show a distinct failure of activation upon calcium re-addition. This hypothesis is contrary to the observations.\nVerdict: **Incorrect**.", "answer": "$$\\boxed{\\text{A, B}}$$", "id": "2871873"}]}